Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com
On Friday, HC Wainwright reaffirmed a Buy rating on biopharmaceutical company argenx SE (NASDAQ: ARGX), with a firm price target of $448.00. The Company's confidence in argenx is rooted in the Company's successful introduction of…
